Chemokine antagonist infusion attenuates cellular infiltration following spinal cord contusion injury in rat.
Spinal cord injury is accompanied by an initial inflammatory reaction followed by secondary injury that is caused, in part, by apoptosis. Recruitment of leukocytes from the blood compartment to the site of inflammation in the injured spinal cord has been attributed to locally generated chemotactic agents (cytokines and chemokines). In addition to upregulation in the message levels of a number of chemokines, we have found up-regulation in the message levels of several chemokine receptors following spinal cord contusion injury. To reduce the inflammatory response after spinal cord injury, we have blocked the interaction of chemokine receptors with their ligands using the vMIPII chemokine antagonist. Using a rat model of spinal cord contusion injury, we show that continuous infusion of the antagonist for up to 7 days results in a decrease in infiltrating hematogenous cells at the site of injury. Histological evaluation ofthe tissue showed fewer activated macrophages at the site of injury. Concomitantly, reduced neuronal loss and gliosis were observed in the antagonist infused spinal cord. In addition, increased expression of Bcl-2 gene, an endogenous inhibitor of apoptosis, was seen in the antagonist infused spinal cord at 7 days post injury. Morphologically, staining with the bisbenzamide dye Hoechst 33342 showed significantly more apoptotic bodies in the vehicle compared to antagonist infused spinal cord. Our data suggest that chemokine antagonist infusion post-injury results in limiting the inflammatory response following spinal cord contusion injury, thereby attenuating neuronal loss, possibly due to decreased apoptosis. These findings support the contention that disrupting chemokine interactions with their receptors may be an effective approach in reducing the secondary damage after spinal cord injury.
Ghirnikar
R S
RS
Department of Pathology, VAPA Health Care System, Palo Alto, CA 94304, USA.
Lee
Y L
YL
Eng
L F
LF
D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D018925:Chemokines / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000494:pharmacology; D019742:Chemokines, CC / Q000494:pharmacology; D005260:Female; D005911:Gliosis / Q000188:drug therapy; D007249:Inflammation / Q000188:drug therapy* / Q000503:physiopathology*; D009474:Neurons / Q000187:drug effects / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D019707:Receptors, Chemokine / Q000187:drug effects / Q000378:metabolism; D013116:Spinal Cord / Q000473:pathology / Q000503:physiopathology; D013119:Spinal Cord Injuries / Q000188:drug therapy* / Q000503:physiopathology*
D018925:Chemokines; D019742:Chemokines, CC; D019707:Receptors, Chemokine; C108059:vMIP-II